Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade to Peer Perform

Key Takeaways

• PLTR shares declined 2% to $131.94 Tuesday, now down 26% year-to-date and 36% off November 2025’s peak of $207.18.
• Wolfe Research raised its rating from Underperform to Peer Perform without issuing a price target.
• Analysts acknowledged Palantir as “the most applied enterprise AI software company” while warning it’s “the most expensive in software.”
• UBS held its Buy rating with $200 target despite growing concerns about rivals like OpenAI, Anthropic, and Databricks.
• Among 32 Wall Street analysts tracked by FactSet, the consensus rating is Overweight with an average target of $189.87, suggesting 44% upside potential.

Palantir Technologies (PLTR) received a rating boost from Wolfe Research on Tuesday. The shares declined anyway, dropping 2%.

That dynamic speaks volumes about current market sentiment toward the AI software maker.

Palantir Technologies Inc., PLTR

Shares closed at $131.94 Tuesday, continuing a difficult period that has erased 26% of the stock’s value in 2026. June alone has brought a 16% decline, leaving PLTR trading 36% beneath its all-time closing high of $207.18 reached on November 3, 2025.

Meanwhile, broader indices tell a different story: the S&P 500 has climbed 10% this year, while the Nasdaq Composite has advanced approximately 14%.

Wolfe Research analysts Alex Zukin and Joshua Tilton reinstated coverage of PLTR with a Peer Perform designation, an improvement from their previous Underperform stance. The firm did not provide a specific price target alongside the upgrade.

Their analysis presents a nuanced picture. While they recognize Palantir as the preeminent applied enterprise AI software provider with industry-leading growth rates, they simultaneously caution that the stock’s valuation “is still the most expensive in software.”

PLTR currently commands a forward price-to-earnings multiple of approximately 77.4x, dramatically higher than the S&P 500’s 21.07x ratio.

“We love the business,” Zukin stated, “and if growth trends closer to our upside scenario we could find ourselves looking at an entry point too good to ignore.” However, the analysts believe the current premium already reflects much of the anticipated growth and margin expansion.

The Ontology Advantage

The Wolfe analysts highlighted Palantir’s Ontology platform as its critical competitive edge. This proprietary database infrastructure bridges AI capabilities with human decision-making to automate enterprise operations. Zukin observed that Ontology sales momentum and backlog are gaining speed in 2026, which he views as an encouraging indicator.

Separately on Tuesday, UBS analyst Karl Keirstead reaffirmed his Buy rating alongside a $200 price target. Keirstead maintained his bullish position following discussions with Palantir leadership that centered largely on competitive dynamics.

The Competitive Landscape

The primary concern raised during the UBS meeting involved whether competitors such as OpenAI, Anthropic, and Databricks — each developing field deployment capabilities and data context infrastructure — might erode Palantir’s ontology advantage.

Palantir executives countered these concerns, emphasizing that their operating system extends far beyond simply deploying large language models or data ingestion. Management expressed confidence that LLM providers would struggle to gain significant traction in the data infrastructure layer.

With an 84% gross profit margin, Palantir demonstrates substantial pricing power and competitive strength, according to UBS.

InvestingPro data reveals that 21 analysts have recently increased their earnings projections for the company.

Additional recent analyst activity includes Rosenblatt reaffirming its Buy rating after client wins and a Google Cloud collaboration unveiled at AIPCon 10. Baird similarly upheld its Outperform rating with a $200 target following investor discussions with Palantir leadership.

On the regulatory front, the UK government has announced plans to review Palantir’s existing contract with the National Health Service.

Among the 32 firms monitored by FactSet, PLTR maintains an average Overweight recommendation with a mean price target of $189.87, implying 44% upside from current trading levels.